SPRY
ARS Pharmaceuticals, Inc.
$9.76
+1.77%
$969.2M
No data for this timeframe.
Vol
Market Cap$969.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders50 funds
Inst. Value$344.7M
Inst. Activity6 buys / 9 sells
Insider Activity0B / 2S
Insider Net $-$283.6K
SEC Reports5
Press Releases2
Recent Activity
Jun 13, 2026
SEC
Two C-suite insiders at ARS Pharmaceuticals (SPRY) sold shares on June 12, 2026, totaling $284K in open-market sales. Th
CLUSTER — Impact 3/10
Jun 12, 2026
Insider
Karas Eric acquired via exercise 25,000 shares
Chief Commercial Officer @ $1.50 ($37.5K)
Jun 12, 2026
Insider
Karas Eric sold 25,000 shares
Chief Commercial Officer @ $10.00 ($250.0K)
Jun 12, 2026
Insider
Fitzpatrick Alexander A sold 3,355 shares
Chief Legal Officer @ $10.00 ($33.5K)
Jun 8, 2026
short_volume
Short Volume: SPRY — 59.8% short (0.5M / 0.9M)
Short: 538,252 | Exempt: 1,676 | TRF Vol: 900,174 | Short Ratio: 59.8% | Off-exchange volume (dark p
May 15, 2026
SEC
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M (up 184% YoY from $8.0M) and a net loss of $60.6M ($0.61/sh
8-K — Impact 5/10
May 15, 2026
SEC
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M, beating the $22.1M consensus, with neffy U.S. net product
PRESS-RELEASE — Impact 6/10
Inst.
Rubric Capital Management LP — ADD
8,000,000 shares ($64.2M)
Price Targets
$28.80
+195.1% upside
Strong Buy
Current $9.76
Low $25.00
Median $30.00
High $32.00
5 analysts
$25.00
$32.00
Analyst Ratings
5Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.53 ▼ -23.3% | $-0.61 — $-0.47 | -15% YoY | 3 |
| Next Q | $-0.33 ▼ -38.9% | $-0.40 — $-0.20 | 37% YoY | 3 |
| Current FY | $-1.76 ▼ -12.3% | $-2.05 — $-1.45 | -1% YoY | 4 |
| Next FY | $-0.96 ▼ -26.4% | $-1.41 — $-0.44 | 46% YoY | 4 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Two C-suite insiders at ARS Pharmaceuticals (SPRY) sold shares on June 12, 2026, totaling $284K in open-market sales. Th
Jun 13, 2026
NEUTRAL
8-K
5/10
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M (up 184% YoY from $8.0M) and a net loss of $60.6M ($0.61/sh
May 15, 2026
BULLISH
Press
7/10
ARS Pharmaceuticals announced FDA approval to remove age restrictions from the prescribing information for neffy 1 mg (e
Mar 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| RA CAPITAL MANAGEMENT, L.P. | $87.2M | — |
| Rubric Capital Management LP | $64.2M | ADD |
| BlackRock, Inc. | $40.2M | — |
| STATE STREET CORP | $29.3M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 12, 2026 | Karas Eric | M | $37.5K |
| Jun 12, 2026 | Karas Eric | SELL | $250.0K |
| Jun 12, 2026 | Fitzpatrick Alexander | SELL | $33.5K |
50 institutional holders with $344.7M total value (42,902,071 shares) as of 2026-Q1. Top holders: NOMURA, RA, Rubric. Net selling activity: 9 institutions trimmed/exited vs 6 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 10,860,977 | $87.2M | 25.3% | — |
| 3 | Rubric Capital Management LP | 8,000,000 | $64.2M | 18.6% | ADD +29.0% |
| 4 | BlackRock, Inc. | 5,012,254 | $40.2M | 11.7% | — |
| 5 | STATE STREET CORP | 3,644,966 | $29.3M | 8.5% | ADD +31.9% |
| 6 | FRANKLIN RESOURCES INC | 3,278,549 | $26.3M | 7.6% | ADD +28.9% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 2,542,504 | $20.4M | 5.9% | — |
| 8 | CITADEL ADVISORS LLC | 1,773,188 | $14.2M | 4.1% | TRIM -29.3% |
| 9 | BAMCO INC /NY/ | 1,273,341 | $10.2M | 3.0% | DOUBLED +3071.3% |
| 10 | GOLDMAN SACHS GROUP INC | 724,219 | $5.8M | 1.7% | — |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 533,394 | $4.3M | 1.2% | — |
| 12 | RAYMOND JAMES FINANCIAL INC | 525,224 | $4.2M | 1.2% | — |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 510,551 | $4.1M | 1.2% | — |
| 14 | FIL Ltd | 455,575 | $3.7M | 1.1% | TRIM -43.8% |
| 15 | VANGUARD FIDUCIARY TRUST CO | 446,307 | $3.6M | 1.0% | — |
| 16 | FIRST TRUST ADVISORS LP | 422,038 | $3.4M | 1.0% | — |
| 17 | FMR LLC | 342,042 | $2.7M | 0.8% | TRIM -46.3% |
| 18 | MORGAN STANLEY | 316,673 | $2.5M | 0.7% | TRIM -42.7% |
| 19 | BANK OF AMERICA CORP /DE/ | 285,728 | $2.3M | 0.7% | TRIM -40.7% |
| 20 | DIMENSIONAL FUND ADVISORS LP | 172,339 | $1.4M | 0.4% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Rubric Capital Management LP | ADD | 6,200,000 | 8,000,000 | +29.0% | $64.2M | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 2,543,097 | 3,278,549 | +28.9% | $26.3M | 2026-Q1 |
| FIL Ltd | TRIM | 810,073 | 455,575 | -43.8% | $3.7M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 552,364 | 316,673 | -42.7% | $2.5M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 482,084 | 285,728 | -40.7% | $2.3M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 79,214 | 105,006 | +32.6% | $843.2K | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 34,128 | 58,373 | +71.0% | $468.7K | 2026-Q1 |
| ROYCE & ASSOCIATES LP | TRIM | 207,051 | 54,024 | -73.9% | $433.8K | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | TRIM | 32,058 | 16,637 | -48.1% | $133.6K | 2026-Q1 |
| SEI INVESTMENTS CO | NEAR_EXIT | 74,807 | 12,983 | -82.6% | $104.3K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | TRIM | 20,620 | 5,647 | -72.6% | $45.3K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 1,894 | 5,454 | +188.0% | $43.8K | 2026-Q1 |
| CWM, LLC | DOUBLED | 62 | 834 | +1245.2% | $6.7K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | NEAR_EXIT | 65,746 | 147 | -99.8% | $1.2K | 2026-Q1 |
| Freestone Grove Partners LP | NEAR_EXIT | 28,003 | 2 | -100.0% | $16.00 | 2026-Q1 |
| Rubric Capital Management LP | ADD | 4,500,000 | 6,200,000 | +37.8% | $72.2M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 272,026 | 482,084 | +77.2% | $5.6M | 2025-Q4 |
| FMR LLC | TRIM | 742,508 | 398,959 | -46.3% | $4.6M | 2025-Q4 |
| Trexquant Investment LP | NEAR_EXIT | 631,720 | 150,100 | -76.2% | $1.7M | 2025-Q4 |
| ALPS ADVISORS INC | ADD | 49,600 | 81,168 | +63.6% | $945.6K | 2025-Q4 |
| MARSHALL WACE, LLP | TRIM | 197,320 | 79,214 | -59.9% | $922.8K | 2025-Q4 |
| SEI INVESTMENTS CO | ADD | 48,112 | 74,807 | +55.5% | $871.5K | 2025-Q4 |
| VOYA INVESTMENT MANAGEMENT LLC | TRIM | 114,853 | 34,128 | -70.3% | $397.6K | 2025-Q4 |
| Freestone Grove Partners LP | NEAR_EXIT | 152,197 | 28,003 | -81.6% | $326.2K | 2025-Q4 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 6,253 | 20,620 | +229.8% | $240.2K | 2025-Q4 |
2 unique insiders with 3 transactions. Net insider value: -$283.6K ($0.00 bought, $283.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | Karas Eric | Chief Commercial Officer | EXERCISE | 25,000 | $1.50 | $37.5K |
| Jun 12, 2026 | Karas Eric | Chief Commercial Officer | SELL | 25,000 | $10.00 | $250.0K |
| Jun 12, 2026 | Fitzpatrick Alexander A | Chief Legal Officer | SELL | 3,355 | $10.00 | $33.5K |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 4 neutral. Avg impact: 4.0/10.
NEUTRAL
CLUSTER
3/10
Two C-suite insiders at ARS Pharmaceuticals (SPRY) sold shares on June 12, 2026, totaling $284K in o
Jun 13, 2026
NEUTRAL
8-K
5/10
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M (up 184% YoY from $8.0M) and a net loss
May 15, 2026
BEARISH
PRESS-RELEASE
6/10
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M, beating the $22.1M consensus, with nef
May 15, 2026
NEUTRAL
8-K
2/10
ARS Pharmaceuticals appointed Donn Casale as President effective June 1, 2026, replacing CEO Richard
May 13, 2026
NEUTRAL
PRESS-RELEASE
4/10
ARS Pharmaceuticals reported Q4 2025 EPS of -$0.42, beating consensus of -$0.54 by 21.5%. The compan
May 7, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 5 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$28.80 mean target
+195.1% upside
Strong Buy (1.00)
$25.00 Low
$32.00 High
| Metric | Value |
|---|---|
| Current Price | $9.76 |
| Target Low | $25.00 |
| Target Mean | $28.80 |
| Target Median | $30.00 |
| Target High | $32.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.53 | $-0.61 | $-0.47 | -15.2% | -23.3% | 0↑ 2↓ | $0.0B | 100.6% | 3 |
| Next Q 2026-09-30 |
$-0.33 | $-0.40 | $-0.20 | 36.5% | -38.9% | 0↑ 1↓ | $0.1B | 57.9% | 3 |
| Current FY 2026-12-31 |
$-1.76 | $-2.05 | $-1.45 | -1.1% | -12.3% | 0↑ 1↓ | $0.1B | 77.2% | 4 |
| Next FY 2027-12-31 |
$-0.96 | $-1.41 | $-0.44 | 45.6% | -26.4% | 0↑ 3↓ | $0.3B | 83.2% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.530 | |
| 7d ago | $-0.530 | |
| 30d ago | $-0.430 | -0.100 |
| 60d ago | $-0.437 | -0.093 |
| 90d ago | $-0.540 | +0.010 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 5 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 6 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 8, 2026
short_volume
Short Volume: SPRY — 59.8% short (0.5M / 0.9M)
Short: 538,252 | Exempt: 1,676 | TRF Vol: 900,174 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: SPRY — 73.2% short (0.4M / 0.6M)
Short: 407,065 | Exempt: 2,016 | TRF Vol: 555,852 | Short Ratio: 73.2% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: SPRY — 59.1% short (0.5M / 0.9M)
Short: 514,253 | Exempt: 0 | TRF Vol: 869,570 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: SPRY — 70.1% short (0.6M / 0.8M)
Short: 567,683 | Exempt: 2,800 | TRF Vol: 809,462 | Short Ratio: 70.1% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: SPRY — 85.1% short (1.0M / 1.2M)
Short: 1,010,801 | Exempt: 610 | TRF Vol: 1,187,430 | Short Ratio: 85.1% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: SPRY — 71.1% short (0.7M / 1.0M)
Short: 733,180 | Exempt: 1,590 | TRF Vol: 1,031,584 | Short Ratio: 71.1% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: SPRY — 66.2% short (0.4M / 0.7M)
Short: 447,275 | Exempt: 0 | TRF Vol: 675,272 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: SPRY — 67.2% short (0.6M / 1.0M)
Short: 649,395 | Exempt: 19,184 | TRF Vol: 965,862 | Short Ratio: 67.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
earnings
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
<p align="center"><em>Q1 2026 total revenue of $22.7 million including </em><strong><em>neffy</em></strong><sup><em>®</em></sup><em> (epinephrine nasa
May 15, 2026
earnings_calendar
SPRY Q1 2026 Earnings After Market Close — 2026-05-15
May 15, 2026
short_volume
Short Volume: SPRY — 70.0% short (0.8M / 1.2M)
Short: 849,648 | Exempt: 42,737 | TRF Vol: 1,214,286 | Short Ratio: 70.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: SPRY — 65.2% short (0.6M / 0.9M)
Short: 613,033 | Exempt: 0 | TRF Vol: 940,808 | Short Ratio: 65.2% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_interest
FTD: SPRY — 75,516 shares ($0.6M) failed to deliver
Settlement: 20260514, Price: $8.01, FTD Value: $604,883.16, ARS PHARMACEUTICALS, INC. COMM
May 13, 2026
short_volume
Short Volume: SPRY — 59.2% short (0.5M / 0.8M)
Short: 481,396 | Exempt: 1,370 | TRF Vol: 812,784 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: SPRY — 57.0% short (0.3M / 0.5M)
Short: 291,999 | Exempt: 704 | TRF Vol: 512,597 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
Clinical Trial
Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares
Phase Phase 2 — COMPLETED